A share price of Ventyx Biosciences Inc [VTYX] is currently trading at $9.92, down -2.07%. An important factor to consider is whether the stock is rising or falling in short-term value. The VTYX shares have gain 16.71% over the last week, with a monthly amount glided 346.85%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 7, March 2024, Ventyx Biosciences Announces $100 Million Private Placement of Common Stock. In a post published today on Yahoo Finance, Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, announced today that it has entered into a stock purchase agreement for the sale of 11,174,000 shares of its common stock at an offering price of $8.95 per share in a private placement to certain qualified institutional buyers and institutional accredited investors. Gross proceeds of the private placement are expected to be approximately $100 million, before deducting placement agent fees and other expenses. The private placement is expected to close on March 11, 2024, subject to the satisfaction of customary closing conditions.
From an analyst’s perspective:
Ventyx Biosciences Inc [NASDAQ: VTYX] stock has seen the most recent analyst activity on November 07, 2023, when Wells Fargo downgraded its rating to a Equal Weight and also revised its price target to $8 from $77. Previously, Stifel downgraded its rating to Hold on November 07, 2023, and kept the price target unchanged to $6. On November 07, 2023, downgrade downgraded it’s rating to Perform. Morgan Stanley downgraded its rating to a Equal-Weight and decreased its price target to $6 on November 07, 2023. H.C. Wainwright downgraded its rating to a Neutral. In a note dated March 21, 2023, Wells Fargo initiated an Overweight rating and provided a target price of $77 on this stock.
Ventyx Biosciences Inc experienced fluctuations in its stock price throughout the past year between $1.87 and $45.09. Currently, Wall Street analysts expect the stock to reach $51.25 within the next 12 months. Ventyx Biosciences Inc [NASDAQ: VTYX] shares were valued at $9.92 at the most recent close of the market. An investor can expect a potential return of 416.63% based on the average VTYX price forecast.
Analyzing the VTYX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.68, Equity is -1.28 and Total Capital is -0.81. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.27 points at the first support level, and at 8.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.03, and for the 2nd resistance point, it is at 12.13.
Ventyx Biosciences Inc [VTYX] reported earnings per share of -$0.79 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.9/share, meaning a difference of $0.11 and a surprise factor of 12.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.92 per share as compared to estimates of -$0.9 per share, a difference of -$0.02 representing a surprise of -2.20%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ventyx Biosciences Inc [NASDAQ:VTYX] is 11.87. On the other hand, the Quick Ratio is 11.87, and the Cash Ratio is 2.32.
Transactions by insiders
Recent insider trading involved Mohan Raju, CEO and President, that happened on Dec 20 ’23 when 58860.0 shares were sold. Chief Scientific Officer, Nuss John completed a deal on Dec 20 ’23 to sell 17628.0 shares. Meanwhile, Chief Business Officer Krueger Christopher W sold 5293.0 shares on Dec 20 ’23.
